Your Local Laboratory For Rapid Whole Plasmid Nanopore Sequencing Results
Located in Cambridge, Source Genomics is a leading provider of genomic services, processing all samples within our UK laboratory. With the introduction of our new SpeedREAD™ data delivery system for Whole Plasmid Nanopore Sequencing, we now offer unrivaled turnaround times.
Why Choose SpeedREAD™?
Milestone payment follows successful target identification and validation in separate project under same collaboration
Cambridge, UK, 03 June 2024: PhoreMost Ltd., has triggered a second milestone payment in its multi-project target discovery collaboration with Boehringer Ingelheim. This was achieved by identifying and validating novel targets supporting Boehringer Ingelheim’s ambition to develop first-in-class therapies, to transform patients’ lives.
CAMBRIDGE and NEWCASTLE, UK, 03 June 2024: DefiniGEN Ltd., and Atelerix Ltd., today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US. The agreement between the companies combines DefiniGEN’s mechanistically relevant iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which prevents loss of function and enables even sensitive samples to remain stable at ambient temperatures for up to two weeks.
The Femtech & Women’s Health edition of ‘Discovery Spark’ champions early stage businesses working to close the gender health gap
Sandwich, Kent, UK / 30th May 2024 / Discovery Park, Kent’s thriving life science and innovation community, announced the selection of 11 promising start-ups in FemTech & Women’s Health to join Discovery Spark, their growth and support programme for early stage businesses.
Three-storey, multi-occupancy building on track to provide fully fitted laboratory suites for fast-growing life science community within the Cambridge cluster
Bruntwood SciTech is announcing the launch of its new Life Science Accelerator programme at Alderley Park in a move aimed at supporting even greater innovation and economic growth in the region.
Cambridge, 30th May 2024: Six life science start-ups looking to develop products and services to make a positive difference to healthcare have been selected for one of Europe’s top incubators based at the Babraham Research Campus in Cambridge – Accelerate@Babraham.
Tokyo, Japan, Oxford and Cambridge, UK, 30 May 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) and PrecisionLife, the Causal AI precision medicine company, today announce the expansion of their strategic R&D partnership into auto-immune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.
RNA sequencing is becoming the gold-standard method for uncovering the cellular mechanisms behind disease. A variety of RNA sequencing techniques have evolved, which provide all-important information on disease causes and progression for more effective treatments.
Read our latest blog here:
https://sourcebioscience.com/comparing-rna-sequencing-techniques/